企業プロフィール
Mirum Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- MIRM
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
83.10 USD (-0.41%)
終値
最終更新: 2026年10月22日
5.62B USD
時価総額
株価変動の要因
2026年10月22日 時点で MIRM は 0.41% 下落し、$83.10 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Rare Liver Disease Company
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases, with particular expertise in disorders involving bile-acid dysregulation and severe cholestatic pruritus. Its model combines a global specialty commercial organization with late-stage internal development programs.
LIVMARLI Cholestatic Disease Franchise
LIVMARLI, an ileal bile acid transporter inhibitor, is marketed for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis. The product anchors Mirum's commercial presence in pediatric and genetically defined liver diseases.
Established Bile-Acid Medicines
Mirum also markets bile-acid therapies for rare metabolic liver conditions, broadening its revenue base and relationships with hepatology centers. These products complement LIVMARLI and support a focused infrastructure for small patient populations requiring specialist diagnosis and long-term treatment.
Late-Stage Hepatology Pipeline
Volixibat is being developed for cholestatic pruritus in primary sclerosing cholangitis and primary biliary cholangitis. Brelovitug targets chronic hepatitis delta, while LIVMARLI lifecycle studies seek to extend the company's lead franchise into additional cholestatic settings.
Pipeline Beyond Liver Disease
Zilurgisertib is an ALK2 inhibitor for fibrodysplasia ossificans progressiva, and MRM-3379 is a PDE4D program for Fragile X syndrome. These assets expand Mirum into rare skeletal and neurodevelopmental diseases while preserving a specialty-pharma operating model.
今後のカタリスト
- FDA PDUFA decision for zilurgisertib in fibrodysplasia ossificans progressiva on September 26, 2026.
- AZURE-1 data for brelovitug in chronic hepatitis delta in the third quarter of 2026 and AZURE-4 data in the fourth quarter of 2026.
- Phase 3 EXPAND results for LIVMARLI in the fourth quarter of 2026.
- Phase 2b VANTAGE results for volixibat in primary sclerosing cholangitis in the first quarter of 2027.
- Potential volixibat NDA submission in primary sclerosing cholangitis in the first half of 2027, subject to FDA discussions.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。